

Abstract of the Disclosure

The present invention relates to the discovery of antibodies able to modulate (prevent or favour) conversion of PrP<sup>c</sup> to PrP<sup>Sc</sup> and to their antigens. Depending on the nature of the antibodies (antagonistic or agonistic), their respective antigens are either conversion factors or  
5 inhibitors of prion replication.